Targeting the MEK and STAT3 Pathways in Combination With PD1 Blockade Immunotherapy in KRAS-mutant Pancreatic Cancer

Mehra S.; Lamichhane P.; Messaggio F.; Dai X.; Dosch A.; Willobee B.; Srinivasan S.; VanSaun M. N.; Nagathihalli N.; Merchant N.

首页> 外文期刊>Pancreas >Targeting the MEK and STAT3 Pathways in Combination With PD1 Blockade Immunotherapy in KRAS-mutant Pancreatic Cancer

【24h】

Targeting the MEK and STAT3 Pathways in Combination With PD1 Blockade Immunotherapy in KRAS-mutant Pancreatic Cancer

机译：靶向MEK和Stat3途径与PD1阻断免疫疗法组合在KRAS-突变体胰腺癌中

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pancreas》 |2019年第10期|共1页
作者
Mehra S.; Lamichhane P.; Messaggio F.; Dai X.; Dosch A.; Willobee B.; Srinivasan S.; VanSaun M. N.; Nagathihalli N.; Merchant N.;
展开▼
作者单位

Univ Miami Miller Sch Med Dept Surg Miami FL 33136 USA;

Univ Miami Miller Sch Med Dept Surg Miami FL 33136 USA;

Univ Miami Miller Sch Med Dept Surg Miami FL 33136 USA;

Univ Miami Miller Sch Med Dept Surg Miami FL 33136 USA;

Univ Miami Miller Sch Med Dept Surg Miami FL 33136 USA;

Univ Miami Miller Sch Med Dept Surg Miami FL 33136 USA;

Univ Miami Miller Sch Med Dept Surg Miami FL 33136 USA;

Univ Miami Miller Sch Med Dept Surg Miami FL 33136 USA;

Univ Miami Miller Sch Med Dept Surg Miami FL 33136 USA;

Univ Miami Miller Sch Med Dept Surg Miami FL 33136 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Targeting the MEK and STAT3 Pathways in Combination With PD1 Blockade Immunotherapy in KRAS-mutant Pancreatic Cancer [J] . Mehra S., Lamichhane P., Messaggio F., Pancreas . 2019,第10期

机译：靶向MEK和Stat3途径与PD1阻断免疫疗法组合在KRAS-突变体胰腺癌中
2. P3.02c-070 Combination Immunotherapy with MEK Inhibitor for Treatment of Kras-Mutant Lung Cancer in Animal Model [J] . Jong Woo Lee, Yu Zhang, Justin Choi, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P3.02C-070组合免疫疗法与MEK抑制剂治疗动物模型中KRAS-突变体肺癌
3. Molecular pathways: The basis for rational combination using MEK inhibitors in KRAS-mutant cancers [J] . OkumuraS., J?nneP.A. Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第16期

机译：分子途径：MEK抑制剂在KRAS突变癌症中合理组合的基础
4. Synergistically Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Blockade of PD1 and IDO [C] . Yanqi Ye, Jinqiang Wang, Quanyin Hu, Society for Biomaterials annual meeting and exposition . 2017

机译：协同经皮免疫疗法可通过阻断PD1和IDO增强抗肿瘤免疫反应
5. Targeting the MEK5, MEK1/2, and/or Pi3k Pathways Reverses Epithelial to Mesenchymal Transition and Enhances Chemotherapeutic Sensitivity in Breast and Brain Cancers with a Mesenchymal Phenotype [D] . Bhatt, Akshita B. 2021

机译：靶向MEK5，MEK1 / 2和/或PI3K途径将上皮细胞转型的上皮性反转，并通过间充质表型提高乳腺癌和脑癌中的化疗敏感性
6. STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway [O] . Zhenlin Wang, Mengchen Yin, Peilin Chu, 2019

机译：STAT3抑制剂通过激活MEK / ERK信号通路使KRAS突变型肺癌对RAF抑制剂敏感
7. P3.02c-070 Combination Immunotherapy with MEK Inhibitor for Treatment of Kras-Mutant Lung Cancer in Animal Model [O] . Jong Woo Lee, Yu Zhang, Justin Choi, 2017

机译：P3.02C-070组合免疫疗法与MEK抑制剂治疗动物模型中KRAS-突变体肺癌

Targeting the MEK and STAT3 Pathways in Combination With PD1 Blockade Immunotherapy in KRAS-mutant Pancreatic Cancer

著录项

相似文献

相关主题

期刊订阅